Skip to main content

Innate Pharma SA

IPHA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001598599

No open-market purchases or sales by Innate Pharma SA insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $354.0K in total; no superinvestor holds it.

Other share classesIPHYF

Q3 2025 vs. Q2 2025

How the institutions holding Innate Pharma SA changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of IPHA: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders990
Shares99.8K81.6K−18.2K (−18.3%)
Value$178.7K$157.9K−$20.7K (−11.6%)

New holders (1)

Institutions that held Innate Pharma SA at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to IPHA in Q3 2025
InstitutionSharesValue% of portfolio
Farther Finance Advisors, LLC10$190.00%

Sold out (1)

Institutions that held Innate Pharma SA at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of IPHA in Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
Millennium Management LLC11,661$20.4K